• Margin expansion target: Supported by rising capacity utilization and operational leverage, gross margins are expected to remain near 60%, while EBITDA margins are projected to approach 30% in FY27.
• Generics business strategy: The company pivoted its formulation strategy toward high-volume genericized molecules and sustainable contract manufacturing, with plans to file several ANDAs this year after two years of subdued pipeline additions.
• Supply chain de-risking: Dependency on China for imports was reduced from two-thirds pre-COVID to about one-third, driven by in-house development and domestic sourcing of key starting materials.
• Capex and hiring: Laurus Labs plans to deploy ₹3,000 crore in capital expenditure over the next 24 months and expand its workforce from around 8,500 to over 10,000 employees within 18 to 24 months.